Akero Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious metabolic diseases. The company's initial focus is on nonalcoholic steatohepatitis ("NASH"), a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease ("NAFLD"), characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, failure, cancer of the liver, and death. The company is developing AKR-001, an analog of fibroblast growth factor 21 ("FGF21"), for NASH and plan to initiate a Phase 2a clinical trial for AKR-001 in NASH patients with fibrosis in the middle of 2019.

Aldeyra Therapeutics is a biotechnology company engaged in developing and commercializing medicines for patients with immune-mediated diseases. The company's primary product candidate, reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. The company has additional product candidates in development for proliferative vitreoretinopathy and other retinal diseases, autoimmune disease, and cancer. The company has discovered and are developing two additional reactive aldehyde species inhibitors, ADX-103 and ADX-629, for the treatment of retinal disease and autoimmune disease, respectively.

Alphatec Holdings is a holding company. Through its wholly owned subsidiaries, Alphatec Spine, Inc. and SafeOp Surgical, Inc., the company is a medical technology company that designs, develops, and markets technology for for the treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's principal procedural offerings include a variety of Spine Approach Technologies?. The company's Spine Approach Technologies are comprised of intra-operative information and neuromonitoring technologies, access systems, interbody implants, fixation systems, and various biologics offerings.

Altimmune is a clinical stage immunotherapeutics company focused on the discovery and development of products to stimulate immune responses for the prevention and treatment of diseases. The company's product candidates include: HepTcell, an immunotherapeutic for patients infected with the hepatitis B virus; ALT-702, a tumor immunostimulant designed to elicit or improve immune responses to cancers; NasoVAX, an intranasally administered recombinant influenza vaccine which stimulates an immune response; NasoShield, an anthrax vaccine designed to provide protection after a single intranasal administration; and SparVax-L, a recombinant protein-based anthrax vaccine designed to require fewer doses.

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of RNA chemistries and several modes of delivery, the company's therapies trigger the RNA interference (RNAi) mechanism to induce knockdown of target genes. The company is focused on developing drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. The company's pipeline includes, among others, ARO-AAT, a candidate for the treatment of liver disease, and ARO-APOC3, which is designed to reduce production of Apolipoprotein C-III, a component of triglyceride rich lipoproteins.

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company serves customers in the State of Pennsylvania.

Calumet Specialty Product Partners is a holding company. Through its subsidiaries, the company is an independent producer of hydrocarbon products in North America. In its specialty products segment, the company processes crude oil and other feedstocks into a variety of customized lubricating oils, white mineral oils, solvents, petrolatums and waxes. The company's specialty products are sold to customers who purchase them as raw material components for basic industrial, consumer and automotive goods. In its fuel products segment, the company processes crude oil into fuel and fuel-related products, including gasoline, diesel, jet fuel, asphalt and heavy fuel oils, and resells purchased crude oil to third party customers.

Concert Pharmaceuticals is a clinical stage biopharmaceutical company. The company's pipeline is focused on utilizing its deuterium and proprietary product platform to develop medications designed to enhance patient outcomes in therapeutic areas including autoimmune diseases and central nervous systems disorders. The company's clinical pipeline of product candidates include: CTP-543, which is for the treatment of moderate-to-severe alopecia areata, an autoimmune disease that results in partial or complete loss of hair on the scalp and body; CTP-692, which is for the adjunctive treatment of schizophrenia; and AVP-786, which is for the treatment of agitation associated with Alzheimer's disease.

Cooper-Standard Holdings is a holding company. Through its subsidiaries, the company is a manufacturer of sealing, fuel and brake delivery, and fluid transfer systems. The company's sealing systems protect vehicle interiors from weather, dust and noise intrusion. In addition, the company's fuel and brake delivery systems sense, deliver and control fluids to fuel and brake systems. The company's fluid transfer systems sense, deliver and control fluid and vapors for powertrain and HVAC operation. The company has four operating segments: North America, Europe, Asia Pacific and South America.

CymaBay Therapeutics is a biopharmaceutical company focused on developing and providing access to therapies for patients with liver and other chronic diseases with unmet medical need. The company's pipeline includes two clinical stage product candidates: seladelpar (MBX-8025), which is a potent and selective agonist of peroxisome proliferator activated receptor delta for the treatment of primary biliary cholangitis; and MBX-2982, which targets G protein-coupled receptor 119, a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. The company has one preclinical stage product candidate, CB-001, which targets G protein-coupled receptor 120.

DMC Global operates two technical product and process business segments, DynaEnergetics and NobelClad, which collectively serve the energy, industrial and infrastructure markets. DynaEnergetics designs, manufactures and distributes products utilized by the global oil and gas industry principally for the perforation of oil and gas wells. NobelClad is a engaged in the production of explosion-welded clad metal plates for use in the construction of corrosion resistant industrial processing equipment and transition joints. Both DynaEnergetics and NobelClad operate through an international network of manufacturing, distribution and sales facilities.

PT Golden Eagle Energy Tbk is an Indonesian-based company engaged in the coal mining industry. The Company operates coal mining activities through its subsidiary, PT Triaryani, the owner of the coal concession in East Kalimantan, and its affiliate, PT Internasional Prima Coal, the owner of three coal concessions in South Sumatera. Its other subsidiaries are PT Rajawali Resources, PT Mega Raya Kusuma, and PT Naga Mas Makmur Jaya. The Company's head office is located in Jakarta, Indonesia.

Harrow Health focuses on the development, production and sale of medications. The company mainly focuses on its ImprimisRx business, which is an ophthalmology pharmaceutical compounding business, and Park Compounding, Inc., which is a pharmacy focused primarily on health and wellness related, customizable pharmaceutical compounding. The company's other subsidiaries include: Eton Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing products utilizing the U.S. Food and Drug Administration 505(b)(2) regulatory pathway; and Surface Pharmaceuticals, Inc., a pharmaceutical company focused on development and commercialization of therapeutics for ocular surface diseases.

HCI Group is a holding company. Through its subsidiaries, the company is engaged in a variety of business activities, including property and casualty insurance, reinsurance, real estate and information technology. The company's property and casualty insurance provides various forms of residential insurance products such as homeowners insurance, flood insurance and wind-only insurance to homeowners, condominium owners and tenants for properties primarily located in Florida. The company's real estate operations consist of various properties it owns and operates for investment purposes and also properties it owns and uses for its own operations. The company's other operations consist of information technology products.

MacroGenics discovers and develops antibody-based therapeutics to modulate the human immune response for the treatment of cancer. The company has a pipeline of product candidates in human clinical testing, including immuno-oncology programs, that have been created using its proprietary antibody-based technology platforms. The company is developing product candidates that target various tumor-associated antigens, including HER2. The company is also developing a franchise of molecules that target programmed cell death protein 1 (PD-1). The company is developing two bispecific DART product candidates that engage PD-1 and lymphocyte-activation gene 3, as well as PD-1 and cytotoxic T-lymphocyte-associated protein 4.

National Western Life Group is a holding company. Through its subsidiary, National Western Life Insurance Company, the company provides a portfolio of individual whole life, universal life and term insurance plans, and annuities, including supplementary riders. The company manages its business between Domestic Insurance Operations, whereby the company is licensed to do business in all states and the District of Columbia, except for New York and products marketed are annuities, universal life insurance, and other life insurance, which include both term and whole life products, and International Insurance Operations, which focuses on foreign nationals in upper socioeconomic classes of other countries.

Nine Energy Service is a completion services provider that provides services integral to the completion of unconventional wells through a range of tools and methodologies. The company's primary service offerings and deployment methods include: Cementing Services, which consist of blending cement and water with various solid and liquid additives to create a cement slurry; Completion Tools, which provides downhole solutions and technology used for multistage completions; Wireline Services, which uses a wireline unit equipped with a spool of wireline that is unwound and lowered into oil and gas wells to convey tools; and Coiled Tubing Services, which perform wellbore intervention operations.

Oramed Pharmaceuticals is a pharmaceutical company. The company is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company's primary product ORMD-0801, is an orally ingestible insulin capsule for the treatment of diabetes. In addition to its key product, the ORMD-0801 insulin capsule, the company is using its technology for an orally ingestible GLP-1 capsule, or ORMD-0901. The company is also developing a new drug candidate, a weight loss treatment in the form of an oral leptin capsule.

PDS Biotechnology is a clinical stage immuno-oncology company with a pipeline of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. All of the company's products are based on the proprietary Versamune? platform technology, which activates and directs the human immune system against cancer cells.

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform that discovers and develops peptide-based drug candidates. The company's product candidates include: PTG-300, which is an injectable hepcidin mimetic for the treatment of patients with beta-thalassemia; PTF-200, which is an oral gastrointestinal (GI)-restricted Interleukin-23 receptor antagonist peptide product candidate for the treatment of inflammatory bowel disease (IBD); and PN-943, which is an oral, alpha-4-beta-7 antagonist for the treatment of IBD. The company is researching oral and injectable peptide-based product candidates for a range of conditions including hematology and GI diseases.

Provention Bio is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. The company's principal product candidates include: PRV-031 (teplizumab, anti-CD3 mAb) for the interception of type 1 diabetes; PRV-015 (anti-IL-15 mAb) for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 (oral CSF-1R inhibitor) for the treatment of Crohn's disease; PRV-300 (anti-TLR3 mAb) for the treatment of ulcerative colitis; and PRV-3279 (humanized anti-CD32B and CD79B bispecific) for the treatment of lupus.

Sutro Biopharma is a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated cell-free protein synthesis platform, XpressCF?, to create a variety of protein therapeutics initially for cancer and autoimmune disorders. The company's two product candidates are wholly owned: STRO-001, an antibody-drug conjugates (ADC) directed against CD74, for patients with multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.

TG Therapeutics is a biopharmaceutical company focuses on developing and delivering medicines for patients with B-cell mediated diseases, including Chronic Lymphocytic Leukemia (CLL), non-Hodgkin's Lymphoma (NHL) and Multiple Sclerosis (MS). The company has developed a B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. The company has five B-cell targeted drug candidates in clinical development, with the two therapies, ublituximab (TG-1101) and umbralisib (TGR-1202), in pivotal trials for CLL, NHL and MS. Ublituximab is an anti-CD20 monoclonal antibody. Umbralisib is an oral, once daily inhibitor of PI3K delta.